NHS Evidence expert commentary: Citalopram for the treatment of depression

Source: NHS Evidence Area: News The February edition of 'Eyes on Evidence', the free monthly e-bulletin from NHS Evidence covering major new published evidence as it emerges with an explanation about what it means for current practice, includes an expert commentary on new data from a Cochrane review of 37 RCTs which assessed the efficacy, acceptability and tolerability of citalopram compared with other antidepressants in the acute-phase treatment of major depression in over 6000 patients.   Citalopram did not differ from most antidepressants in the primary outcome, the number of patients who responded to treatment in the acute phase. However, it was more effective than paroxetine and reboxetine and less effective than escitalopram. Fewer patients allocated to citalopram withdrew from trials because of adverse events compared with patients allocated to tricyclics and also, fewer patients on citalopram reported at least one side effect than those allocated to reboxetine or venlafaxine. The conclusions of ...
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news